Telomir Pharmaceuticals, Inc.
TELO
$1.22
$0.032.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 63.46% | 25.96% | 37.01% | 51.00% | 14.21% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -100.00% |
| Total Other Non-Cash Items | -92.97% | -42.74% | -12.39% | -32.16% | 74.14% |
| Change in Net Operating Assets | 135.60% | -285.79% | 370.49% | -452.97% | 88.75% |
| Cash from Operations | -55.14% | -15.13% | 27.26% | 44.30% | 51.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 387.24% | -- | -- | -- | -104.80% |
| Total Debt Repaid | -- | -- | -- | -100.00% | 100.00% |
| Issuance of Common Stock | 308.22% | 820.97% | 39.05% | 61.87% | -64.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 698.01% | -- | -- | 100.00% | 153.40% |
| Cash from Financing | 357.78% | 768.91% | 53.25% | 50.18% | -75.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 490.93% | 279.62% | 375.97% | 680.43% | -160.43% |